Eolas Therapeutics is a biotechnology company focused on developing novel therapies for addiction and other neurological disorders. Our mission is to improve the lives of patients by addressing unmet medical needs through innovative science and a patient-centric approach.
At Eolas Therapeutics, we leverage cutting-edge neuroscience to develop therapies that target the brain's reward system. Our approach focuses on modulating specific neural pathways to treat addiction and related disorders, offering hope for patients with limited treatment options.
| Program | Indication | Stage |
|---|---|---|
| AZD-4041 | Opiod-Use Disorder | Phase II |
| EORA-204 | Cocaine-Use Disorder | Phase I |
| EORA-213 | Alcohol-Use Disorder | Phase I |
Join our team to make a difference in the lives of patients. We are always looking for talented individuals passionate about advancing neuroscience. Check back for open positions.
Eolas Therapeutics awarded a $2M grant to advance EOL-101 development.
Our team published findings on neural reward pathways in Nature.
Eolas Therapeutics Secures Full Development Rights to AZD-4041.
Eolas Therapeutics receives Notice of Award for $7.5M grant to advance AZD-4041 into Phase II Clinical Trials.